172 related articles for article (PubMed ID: 17262082)
41. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.
Fabi A; Di Benedetto A; Metro G; Perracchio L; Nisticò C; Di Filippo F; Ercolani C; Ferretti G; Melucci E; Buglioni S; Sperduti I; Papaldo P; Cognetti F; Mottolese M
Clin Cancer Res; 2011 Apr; 17(7):2055-64. PubMed ID: 21307144
[TBL] [Abstract][Full Text] [Related]
42. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas.
Cho EY; Srivastava A; Park K; Kim J; Lee MH; Do I; Lee J; Kim KM; Sohn TS; Kang WK; Kim S
Pathology; 2012 Apr; 44(3):216-20. PubMed ID: 22437741
[TBL] [Abstract][Full Text] [Related]
43. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
44. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor.
Krawczyk N; Banys M; Neubauer H; Solomayer EF; Gall C; Hahn M; Becker S; Bachmann R; Wallwiener D; Fehm T
Anticancer Res; 2009 Oct; 29(10):4019-24. PubMed ID: 19846945
[TBL] [Abstract][Full Text] [Related]
45. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.
Pestrin M; Bessi S; Galardi F; Truglia M; Biggeri A; Biagioni C; Cappadona S; Biganzoli L; Giannini A; Di Leo A
Breast Cancer Res Treat; 2009 Dec; 118(3):523-30. PubMed ID: 19597704
[TBL] [Abstract][Full Text] [Related]
46. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
Bilous M; Morey A; Armes J; Cummings M; Francis G
Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
[TBL] [Abstract][Full Text] [Related]
47. Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.
Hwang CC; Pintye M; Chang LC; Chen HY; Yeh KY; Chein HP; Lee N; Chen JR
Histopathology; 2011 Nov; 59(5):984-92. PubMed ID: 22092410
[TBL] [Abstract][Full Text] [Related]
48. Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot study.
Valladares-Ayerbes M; Iglesias-Díaz P; Díaz-Prado S; Ayude D; Medina V; Haz M; Reboredo M; Antolín S; Calvo L; Antón-Aparicio LM
J Cancer Res Clin Oncol; 2009 Sep; 135(9):1185-95. PubMed ID: 19221791
[TBL] [Abstract][Full Text] [Related]
49. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
[TBL] [Abstract][Full Text] [Related]
50. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
[TBL] [Abstract][Full Text] [Related]
51. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer.
Zhu X; Lu Y; Lu H; Yang W; Tu X; Cai X; Zhou X
Hum Pathol; 2011 Oct; 42(10):1499-504. PubMed ID: 21676436
[TBL] [Abstract][Full Text] [Related]
52. Sensitive fluorescent in situ hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates.
Forus A; Høifødt HK; Overli GE; Myklebost O; Fodstad O
Mol Pathol; 1999 Apr; 52(2):68-74. PubMed ID: 10474684
[TBL] [Abstract][Full Text] [Related]
53. Whether to determine HER2 status for breast cancer in the primary tumour or in the metastasis.
Santiago MP; Vázquez-Boquete A; Fernández B; Masa C; Antúnez JR; Fraga M; Forteza J; García-Caballero T
Histol Histopathol; 2009 Jun; 24(6):675-82. PubMed ID: 19337966
[TBL] [Abstract][Full Text] [Related]
54. Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients.
Rack B; Zombirt E; Trapp E; Jückstock J; Andergassen U; Neugebauer J; Kost B; Weissenbacher T; Jeschke U; Schindlbeck C; Janni W; Alunni-Fabbroni M
Oncology; 2016; 90(4):232-8. PubMed ID: 26937631
[TBL] [Abstract][Full Text] [Related]
55. HER2-positive DTCs/CTCs in breast cancer.
Hartkopf AD; Banys M; Fehm T
Recent Results Cancer Res; 2012; 195():203-15. PubMed ID: 22527508
[TBL] [Abstract][Full Text] [Related]
56. Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance.
Choesmel V; Pierga JY; Nos C; Vincent-Salomon A; Sigal-Zafrani B; Thiery JP; Blin N
Breast Cancer Res; 2004; 6(5):R556-70. PubMed ID: 15318937
[TBL] [Abstract][Full Text] [Related]
57. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: towards a novel surrogate test to monitor adjuvant therapies of solid tumours.
Schlimok G; Pantel K; Loibner H; Fackler-Schwalbe I; Riethmüller G
Eur J Cancer; 1995 Oct; 31A(11):1799-803. PubMed ID: 8541104
[TBL] [Abstract][Full Text] [Related]
58. Detection of bone marrow micrometastases in the rib marrow of head and neck cancer patients: a prospective pilot study.
Skinner LJ; Conlon BJ; Russell JD; O'sullivan GC; O'dwyer TP
Eur Arch Otorhinolaryngol; 2005 Feb; 262(2):103-6. PubMed ID: 15197562
[TBL] [Abstract][Full Text] [Related]
59. A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow.
Vredenburgh JJ; Silva O; Tyer C; DeSombre K; Abou-Ghalia A; Cook M; Layfield L; Peters WP; Bast RC
J Hematother; 1996 Feb; 5(1):57-62. PubMed ID: 8646482
[TBL] [Abstract][Full Text] [Related]
60. Detection of HER2 amplification in circulating free DNA in patients with breast cancer.
Page K; Hava N; Ward B; Brown J; Guttery DS; Ruangpratheep C; Blighe K; Sharma A; Walker RA; Coombes RC; Shaw JA
Br J Cancer; 2011 Apr; 104(8):1342-8. PubMed ID: 21427727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
